UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Lysine-Specific Demethylase 1 (LSD1/KDM1A) Inhibition as a Target for Disease Modification in Myelofibrosis

Cells (Basel, Switzerland), 2022-07, Vol.11 (13), p.2107

Gill, Harinder

2022

Volltextzugriff (PDF)

Correction: Gill, H. Lysine-Specific Demethylase 1 (LSD1/KDM1A) Inhibition as a Target for Disease Modification in Myelofibrosis. Cells 2022, 11 , 2107

Cells (Basel, Switzerland), 2022-12, Vol.11 (24), p.4126

Gill, Harinder

2022

Volltextzugriff (PDF)

Pathogenesis and Treatment of Leukemia

1, 2023

Volltextzugriff (PDF)

Targeting and Monitoring Acute Myeloid Leukaemia with Nucleophosmin-1 ( NPM1 ) Mutation

International journal of molecular sciences, 2023-02, Vol.24 (4), p.3161

2023

Volltextzugriff (PDF)

Rethinking Palliative Care in Psychiatry

JAMA psychiatry (Chicago, Ill.), 2023-11, Vol.80 (11), p.1089

2023

Volltextzugriff (PDF)

Adding the epigenomic signature to the prognostic jigsaw of myelodysplastic neoplasm?

British journal of haematology, 2024-05, Vol.204 (5), p.1577-1578

Gill, Harinder

2024

Volltextzugriff (PDF)

Oral arsenic trioxide, all‐trans retinoic acid, and ascorbic acid maintenance after first complete remission in acute promyelocytic leukemia: Long‐term results and unique prognostic indicators

Cancer, 2020-07, Vol.126 (14), p.3244-3254

2020

Volltextzugriff (PDF)

Molecular Targeted Therapy and Immunotherapy for Myelodysplastic Syndrome

International journal of molecular sciences, 2021-10, Vol.22 (19), p.10232

2021

Volltextzugriff (PDF)

Editorial: Acute promyelocytic leukemia - towards a chemotherapy-free approach to cure in all patients, Volume II

Frontiers in oncology, 2023-06, Vol.13, p.1238486-1238486

2023

Volltextzugriff (PDF)

Oral arsenic trioxide for treating acute promyelocytic leukaemia: Implications for its worldwide epidemiology and beyond

Frontiers in oncology, 2022-11, Vol.12, p.1026478-1026478

2022

Volltextzugriff (PDF)

Editorial: Acute Promyelocytic Leukemia - Towards A Chemotherapy-Free Approach to Cure in All Patients

Frontiers in oncology, 2022-01, Vol.11, p.831308-831308

2022

Volltextzugriff (PDF)

Resurrection of Oral Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: A Historical Account From Bedside to Bench to Bedside

Frontiers in oncology, 2020-08, Vol.10, p.1294-1294

2020

Volltextzugriff (PDF)

Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms

International journal of molecular sciences, 2021-01, Vol.22 (2), p.659

2021

Volltextzugriff (PDF)

Chemotherapy-free approaches to newly-diagnosed acute promyelocytic leukaemia: is oral-arsenic trioxide/all-trans retinoic acid/ascorbic acid the answer?

Expert review of hematology, 2024-10, Vol.17 (10), p.661-667

Gill, Harinder

2024

Volltextzugriff (PDF)

The Development and Clinical Applications of Oral Arsenic Trioxide for Acute Promyelocytic Leukaemia and Other Diseases

Pharmaceutics, 2022-09, Vol.14 (9), p.1945

2022

Volltextzugriff (PDF)

Undiagnosed Hypertension in Vancouver’s Punjabi Sikh Community: A Cross-Sectional Study

Journal of immigrant and minority health, 2022-10, Vol.24 (5), p.1371-1374

2022

Volltextzugriff (PDF)

Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy

International Journal of Molecular Sciences, 2016-03, Vol.17 (4), p.440-440

2016

Volltextzugriff (PDF)

Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021

BMC cancer, 2023-02, Vol.23 (1), p.141-141, Article 141

2023

Volltextzugriff (PDF)

Epigenetic Silencing of PTEN and Epi-Transcriptional Silencing of MDM2 Underlied Progression to Secondary Acute Myeloid Leukemia in Myelodysplastic Syndrome Treated with Hypomethylating Agents

International journal of molecular sciences, 2022-05, Vol.23 (10), p.5670

2022

Volltextzugriff (PDF)

Disseminated Infections with Talaromyces marneffei in Non-AIDS Patients Given Monoclonal Antibodies against CD20 and Kinase Inhibitors

Emerging infectious diseases, 2015-07, Vol.21 (7), p.1101-1106

2015

Volltextzugriff (PDF)

Single-Nucleotide Variations, Insertions/Deletions and Copy Number Variations in Myelodysplastic Syndrome during Disease Progression Revealed by a Single-Cell DNA Sequencing Platform

International journal of molecular sciences, 2022-04, Vol.23 (9), p.4647

2022

Volltextzugriff (PDF)

Gain-of-function KCNJ6 Mutation in a Severe Hyperkinetic Movement Disorder Phenotype

Neuroscience, 2018-08, Vol.384, p.152-164

2018

Volltextzugriff (PDF)

Correction: Gill, H. Lysine-Specific Demethylase 1 Inhibition as a Target for Disease Modification in Myelofibrosis. ICells/I 2022, I11/I, 2107

Cells (Basel, Switzerland), 2022-12, Vol.11 (24)

Gill, Harinder

2022

Volltextzugriff (PDF)

A novel tescalcin-sodium/hydrogen exchange axis underlying sorafenib resistance in FLT3-ITD+ AML

Blood, 2014-04, Vol.123 (16), p.2530-2539

2014

Volltextzugriff (PDF)

Complexities in delivering end-of-life care in accordance with patient desires that have been documented

Annals of palliative medicine, 2023-03, Vol.12 (2), p.258-261

2023

Volltextzugriff (PDF)

1 – 25 von 228

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(150)
Mit Volltextzugriff
(203)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(228)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Lysine-Specific Demethylase 1 (LSD1/KDM1A) Inhibition as a Target for Disease Modification in Myelofibrosis

Correction: Gill, H. Lysine-Specific Demethylase 1 (LSD1/KDM1A) Inhibition as a Target for Disease Modification in Myelofibrosis. Cells 2022, 11 , 2107

Pathogenesis and Treatment of Leukemia

Targeting and Monitoring Acute Myeloid Leukaemia with Nucleophosmin-1 ( NPM1 ) Mutation

Rethinking Palliative Care in Psychiatry

Adding the epigenomic signature to the prognostic jigsaw of myelodysplastic neoplasm?

Oral arsenic trioxide, all‐trans retinoic acid, and ascorbic acid maintenance after first complete remission in acute promyelocytic leukemia: Long‐term results and unique prognostic indicators

Molecular Targeted Therapy and Immunotherapy for Myelodysplastic Syndrome

Editorial: Acute promyelocytic leukemia - towards a chemotherapy-free approach to cure in all patients, Volume II

Oral arsenic trioxide for treating acute promyelocytic leukaemia: Implications for its worldwide epidemiology and beyond

Editorial: Acute Promyelocytic Leukemia - Towards A Chemotherapy-Free Approach to Cure in All Patients

Resurrection of Oral Arsenic Trioxide for Treating Acute Promyelocytic Leukaemia: A Historical Account From Bedside to Bench to Bedside

Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms

Chemotherapy-free approaches to newly-diagnosed acute promyelocytic leukaemia: is oral-arsenic trioxide/all-trans retinoic acid/ascorbic acid the answer?

The Development and Clinical Applications of Oral Arsenic Trioxide for Acute Promyelocytic Leukaemia and Other Diseases

Undiagnosed Hypertension in Vancouver’s Punjabi Sikh Community: A Cross-Sectional Study

Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy

Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021

Epigenetic Silencing of PTEN and Epi-Transcriptional Silencing of MDM2 Underlied Progression to Secondary Acute Myeloid Leukemia in Myelodysplastic Syndrome Treated with Hypomethylating Agents

Disseminated Infections with Talaromyces marneffei in Non-AIDS Patients Given Monoclonal Antibodies against CD20 and Kinase Inhibitors

Single-Nucleotide Variations, Insertions/Deletions and Copy Number Variations in Myelodysplastic Syndrome during Disease Progression Revealed by a Single-Cell DNA Sequencing Platform

Gain-of-function KCNJ6 Mutation in a Severe Hyperkinetic Movement Disorder Phenotype

Correction: Gill, H. Lysine-Specific Demethylase 1 Inhibition as a Target for Disease Modification in Myelofibrosis. ICells/I 2022, I11/I, 2107

A novel tescalcin-sodium/hydrogen exchange axis underlying sorafenib resistance in FLT3-ITD+ AML

Complexities in delivering end-of-life care in accordance with patient desires that have been documented

Suchergebnisse filtern